Barton Investment Management held its stake in shares of AbbVie Inc. (NYSE:ABBV) during the first quarter, Holdings Channel reports. The firm owned 9,828 shares of the company’s stock at the end of the first quarter. AbbVie comprises 0.2% of Barton Investment Management’s investment portfolio, making the stock its 27th largest position. Barton Investment Management’s holdings in AbbVie were worth $640,000 at the end of the most recent quarter.
A number of other hedge funds have also modified their holdings of ABBV. State Street Corp raised its position in AbbVie by 4.0% in the fourth quarter. State Street Corp now owns 71,273,488 shares of the company’s stock valued at $4,463,150,000 after buying an additional 2,763,770 shares in the last quarter. Federated Investors Inc. PA raised its position in AbbVie by 0.6% in the fourth quarter. Federated Investors Inc. PA now owns 15,058,050 shares of the company’s stock valued at $942,935,000 after buying an additional 94,872 shares in the last quarter. Norges Bank purchased a new position in AbbVie during the fourth quarter valued at approximately $823,984,000. Glenview Capital Management LLC purchased a new position in AbbVie during the fourth quarter valued at approximately $570,905,000. Finally, Prudential PLC raised its position in AbbVie by 12.6% in the fourth quarter. Prudential PLC now owns 7,011,026 shares of the company’s stock valued at $439,030,000 after buying an additional 786,487 shares in the last quarter. Institutional investors and hedge funds own 68.02% of the company’s stock.
AbbVie Inc. (NYSE ABBV) opened at 72.74 on Tuesday. The stock has a 50 day moving average of $67.41 and a 200-day moving average of $64.18. The firm has a market cap of $115.77 billion, a P/E ratio of 18.85 and a beta of 1.52. AbbVie Inc. has a 12 month low of $55.06 and a 12 month high of $72.94.
AbbVie (NYSE:ABBV) last released its earnings results on Thursday, April 27th. The company reported $1.28 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.26 by $0.02. The firm had revenue of $6.54 billion for the quarter, compared to the consensus estimate of $6.49 billion. AbbVie had a return on equity of 148.83% and a net margin of 24.07%. The company’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.15 EPS. Equities research analysts predict that AbbVie Inc. will post $5.53 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, August 15th. Stockholders of record on Friday, July 14th will be given a dividend of $0.64 per share. This represents a $2.56 annualized dividend and a dividend yield of 3.52%. The ex-dividend date of this dividend is Wednesday, July 12th. AbbVie’s dividend payout ratio is currently 66.32%.
ABBV has been the topic of several recent analyst reports. Vetr raised shares of AbbVie from a “buy” rating to a “strong-buy” rating and set a $74.38 target price on the stock in a report on Monday, May 8th. BMO Capital Markets set a $63.00 target price on shares of AbbVie and gave the company a “hold” rating in a report on Thursday, April 27th. BidaskClub raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 10th. Societe Generale raised shares of AbbVie from a “sell” rating to a “hold” rating in a report on Wednesday, March 22nd. Finally, Leerink Swann reaffirmed a “market perform” rating on shares of AbbVie in a report on Thursday, June 22nd. Eight research analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. AbbVie presently has a consensus rating of “Buy” and a consensus target price of $73.27.
In other AbbVie news, EVP Carlos Alban sold 45,800 shares of the company’s stock in a transaction on Wednesday, June 14th. The stock was sold at an average price of $70.00, for a total value of $3,206,000.00. Following the transaction, the executive vice president now owns 160,545 shares of the company’s stock, valued at approximately $11,238,150. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO William J. Chase sold 38,300 shares of the company’s stock in a transaction on Thursday, May 18th. The shares were sold at an average price of $65.35, for a total value of $2,502,905.00. Following the completion of the transaction, the chief financial officer now directly owns 209,043 shares in the company, valued at approximately $13,660,960.05. The disclosure for this sale can be found here. In the last three months, insiders have sold 278,135 shares of company stock worth $18,841,085. Corporate insiders own 0.23% of the company’s stock.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV).
Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.